Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$9.46
+1.8%
$9.62
$8.37
$13.14
$17.12B0.23190,815 shs104,867 shs
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$182.50
$182.82
$99.91
$187.45
$40.34B1.253.31 million shs10 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$552.58
+0.9%
$547.51
$476.49
$1,211.20
$59.66B0.33909,261 shs843,779 shs
Shiseido Co. stock logo
SSDOY
Shiseido
$18.30
+4.6%
$16.80
$15.32
$32.17
$7.31B0.3788,675 shs13,638 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
-0.75%-3.33%-3.69%+3.11%-7.05%
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.79%+2.40%+11.06%-5.02%-47.94%
Shiseido Co. stock logo
SSDOY
Shiseido
-1.91%-4.65%+6.24%+10.06%-39.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.9174 of 5 stars
4.45.01.72.32.11.71.9
Shiseido Co. stock logo
SSDOY
Shiseido
2.1004 of 5 stars
0.05.00.80.02.00.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00
N/AN/AN/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.00
N/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.80
Moderate Buy$813.5747.23% Upside
Shiseido Co. stock logo
SSDOY
Shiseido
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest REGN, ALPMY, SSDOY, and ALXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/9/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.00
6/5/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$700.00 ➝ $650.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.00
5/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold$662.00
5/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$700.00 ➝ $580.00
5/27/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$943.00 ➝ $662.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$12.56B1.36$1.82 per share5.20$5.52 per share1.71
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$6.07B6.65$22.81 per share8.00$53.24 per share3.43
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.20B4.20$46.95 per share11.77$268.50 per share2.06
Shiseido Co. stock logo
SSDOY
Shiseido
$6.55B1.12$1.05 per share17.35$10.44 per share1.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$334.93M$0.1755.6513.91N/A2.65%16.55%7.35%7/29/2025 (Estimated)
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$603.40M$11.6059.6413.150.9310.89%23.43%15.06%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$39.2814.0714.531.9831.94%15.27%11.93%8/1/2025 (Estimated)
Shiseido Co. stock logo
SSDOY
Shiseido
-$68.94M-$0.07N/A22.05N/A-0.40%-0.61%-0.30%8/6/2025 (Estimated)

Latest REGN, ALPMY, SSDOY, and ALXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q2 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.53N/AN/AN/A$3.30 billionN/A
5/12/2025Q1 2025
Shiseido Co. stock logo
SSDOY
Shiseido
$0.0569$0.06+$0.0031$0.06$1.72 billion$1.54 billion
4/29/2025Q1 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billion
4/25/2025Q4 2025
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.1474$0.27+$0.1226$0.27$3.02 billion$3.22 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.343.59%N/A200.00%N/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.520.64%N/A8.96%N/A
Shiseido Co. stock logo
SSDOY
Shiseido
$0.080.44%N/AN/A N/A

Latest REGN, ALPMY, SSDOY, and ALXN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/20/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.6%5/20/20255/20/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.37
1.13
0.85
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.19
4.52
3.96
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.93
4.03
Shiseido Co. stock logo
SSDOY
Shiseido
0.36
1.20
0.79

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
82.94%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Shiseido Co. stock logo
SSDOY
Shiseido
0.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,7541.81 billionN/ANot Optionable
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
3,837221.02 millionN/AOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,106107.96 million100.39 millionOptionable
Shiseido Co. stock logo
SSDOY
Shiseido
27,908399.66 millionN/ANot Optionable

Recent News About These Companies

Shiseido (OTCMKTS:SSDOY) Shares Gap Down - Here's Why
Shiseido Restructures Executive Leadership in Japan
Shiseido Q1 disappoints as Drunk Elephant drags down sales
Shiseido Returns to Profit in Q1 Despite Decline in Sales
Shiseido Americas announces Interim CEO as Ron Gee resigns
Shiseido Americas CEO Ron Gee departs amid sales slowdown

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$9.46 +0.17 (+1.83%)
As of 03:58 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Alexion Pharmaceuticals stock logo

Alexion Pharmaceuticals NASDAQ:ALXN

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$552.58 +4.83 (+0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$551.50 -1.08 (-0.20%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Shiseido stock logo

Shiseido OTCMKTS:SSDOY

$18.30 +0.80 (+4.57%)
As of 03:58 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.